Yogesh Mittal, MD
Orthopaedic Surgery · Tulsa, OKNPI 1770545253
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $5,351,009 of the $6,589,542 with a category attached, or 81.2%. Stryker accounts for 99.3% of it on its own, with 17 other manufacturers making up the rest. Among orthopaedic surgery clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,413 payments — averaging $4663.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$6.5M
- Omnilife Science, Inc$45K
- Zimmer Biomet$170
- Globus Medical$123
- Davol Inc.$114
- Smith+Nephew$88
- plus $475 from 12 others
Across 35 payments — averaging $3848.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Stryker$87K
- Brixton Biosciences, Inc.$48K
What the payments were for
- Royalty or licence$5,351,00981%
- Consulting fees$926,82414%
- Travel & lodging$283,4024%
- Food & beverage$28,3080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 1,386 | $6,543,948 |
| Omnilife Science, Inc | 5 | $44,624 |
| Zimmer Biomet | 2 | $170 |
| Globus Medical | 1 | $123 |
| Davol Inc. | 2 | $114 |
| Smith+Nephew | 3 | $88 |
| Orthalign Inc | 2 | $74 |
| Biocomposites Inc | 1 | $65 |
| Pylant Medical | 1 | $54 |
| Pacira Pharmaceuticals Incorporated | 1 | $49 |
| Brixton Biosciences, Inc. | 1 | $42 |
| Si-bone, Inc. | 1 | $42 |
| Kowa Pharmaceuticals America, Inc. | 1 | $35 |
| Johnson & Johnson | 1 | $32 |
| Next Science LLC | 1 | $31 |
| Pfizer | 2 | $26 |
| Bioventus LLC | 1 | $15 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MAKO$6,511,155
- TRIATHLON$33,824
- TRITANIUM$17,625
- PERFORMANCE SOLUTIONS$15,360
- NA$12,000
- NEW PRODUCT DEVELOPMENT$1,618
- MOTIONSENSE DIGITAL GONIOMETER$1,300
- RESTORIS$861
- ORTHOMAP$848
- ACCOLADE$513
- GMRS$228
- TRIDENT$163
- Actify$123
- INSIGNIA$104
How this compares
$6,589,542 in reported general payments places this provider in the 95th percentile of 263 orthopaedic surgery providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 603 | $12,589 |
| EliquisApixaban | 18 | $7,604 |
| Oxycodone Hcl | 1,174 | $7,598 |
| Tranexamic Acid | 429 | $6,130 |
| Gabapentin | 691 | $6,095 |
| Cefadroxil | 675 | $4,442 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 302 | $3,285 |
| Doxycycline Hyclate | 43 | $1,757 |
| Tramadol Hcl | 206 | $754 |
| Clindamycin Hcl | 79 | $614 |
| Naproxen | 59 | $551 |
| Ciprofloxacin Hcl | 62 | $349 |
| Diclofenac Sodium | 27 | $345 |
| Meloxicam | 53 | $324 |
| Amoxicillin | 161 | $284 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $26 | $7,60418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 263 orthopaedic surgery providers in Oklahoma.
Other orthopaedic surgery in Tulsa
- Brian ChalkinTulsa$183K
- Kasra AhmadiniaTulsa$138K
- Sarat KunapuliTulsa$136K
- Keivan AbtahiTulsa$77K
- Rodney PlasterTulsa$61K
- Garrett WallerTulsa$52K
- Landon StallingsTulsa$46K
- Travis SmallTulsa$39K
- Blake ShockleyTulsa$39K
- Chad CrawleyTulsa$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.